Citations

Clear

426 citation(s) found for "ST, Reza".

Role of Colchicine in Reducing Atrial Fibrillation Recurrence After Catheter Ablation
Kanaan, Christopher , Ibrahim, Ramzi , Pham, Hoang Nhat , Abdelnabi, Mahmoud , Habib, Eiad , Farina, Juan M. , Narayanasamy, Hemalatha , Chahal, C. Anwar A. , Arsanjani, Reza , Shen, Win‐Kuang , Masry, Hicham El , Sorajja, Dan , Kanaan, Christopher N , Farina, Juan M , Narayanasamy, Hema , Chahal, Choudhary Anwar A , El Masry, Hicham , Arsanjani, Reza , Nhat, Hoang , Ibrahim, Ramzi

Mayo Clinic

Journal of the American Heart Association | August 23, 2025 | Volume: 14 | Issue: 17 | Pages: No page available

10.1161/jaha.125.041827 | PMID 40847498 Get It

Prognostication Following Transcatheter Edge-to-Edge Mitral Valve Repair Using Combined Echocardiography-Derived Velocity Time Integral Ratio and Artificial Intelligence Applied to Electrocardiogram
Bismee, Nadera N. , Scalia, Isabel G. , Abbas, Mohammed Tiseer , Farina, Juan M. , Pereyra, Milagros , Ali, Nima Baba , Esfahani, Sogol Attaripour , Sheashaa, Hesham, Ibrahim, Omar , Abdelfattah, Fatmaelzahraa , Fortuin, F. David , Lester, Steven J., Sweeney, John P., Arsanjani, Reza , Esfahani, Shadi A. , Pereyra, Milagros , Baba Ali, Nima , Javadi, Niloofar , Sheashaa, Hesham , Ibrahim, Omar H , Abdelfattah, Fatmaelzahraa , Arsanjani, Reza , Farina, Juan M , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Journal of Personalized Medicine | August 13, 2025 | Volume: 15 | Issue: 8 | Pages: 371

10.3390/jpm15080371 | PMID 40863433 Get It

Introduction: Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a minimally invasive option for high-risk surgical candidates with severe and symptomatic mitral regurgitation (MR), but post-procedure residual mitral valve (MV) dysfunction remains a significant concern. This study evaluates the clinical utility of combining artificial intelligence applied to electrocardiograms (ECG-AI) for diastolic dysfunction (DD) grading and the echocardiography-derived velocity time integral of the MV and left ventricular outflow tract ratio (VTIMV/LVOT) in predicting prognosis in patients post-M-TEER. Methods: A retrospective analysis of patients who underwent M-TEER between 2014 and 2021 was conducted. Patients were categorized based on VTIMV/LVOT and ECG-AI scores into three groups: both normal parameters, either abnormal parameter, or both abnormal parameters to compare outcomes (mortality, major adverse cardiovascular events [MACE], and the need for subsequent MV reintervention) using Kaplan–Meier analysis, multivariable Cox regression models, and net reclassification improvement. Results: Overall, 250 patients were included; the median age was 79.5 (IQR: 73.1, 84.6) and 66.4% were male. The combined abnormal VTIMV/LVOT (≥2.5) and ECG-AI score for DD (>1) was associated with higher risk of one-year mortality (adjusted HR: 4.56 [1.04–19.89], p = 0.044) and MACE (adjusted HR: 3.72 [1.09–12.72], p = 0.037) compared to patients with both normal parameters. Conclusions: This study highlights the potential additive value of integrating VTIMV/LVOT and ECG-AI scores as a prognostic tool for a personalized approach to the post-operative evaluation and risk stratification in M-TEER patients.
Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Clyde, Danielle , Grant, Callum, Canales, Juan Andres Aguiar, Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Goodpaster, Kasey , Hopkins, George, Jatana, Anita , Kothari, Shanu N. , Kow, Lillian, Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Ratcliffe, Denise , Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Voon, Kelvin , Lamb, Peter , Mahawar, Kamal , Grant, Callum, Canales, Juan Andres Aguiar, Cameron, David, Copăescu, Cătălin , Clare, Ken , Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Hazebroek, Eric J. , Husain, Farah Anwari , Joyce, Brian, Kermansaravi, Mohammad , Miras, Alexander Dimitri , Moizé, Violeta , Neto, Manoel Galvão , Peterli, Ralph , Sakran, Nasser , Salminen, Paulina , Singhal, Rishi , Stenberg, Erik , Tahrani, Abd A. , Vilallonga, Ramón , Welbourn, Richard , Zerrweck, Carlos , Moussa, Osama , Byrne, James Patrick , Parmar, Chetan D. , Ghanem, Omar M. , Robertson, Andrew G. , Yang, Wah

Mayo Clinic

No container title available | August 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6779565/v1 Get It

Abstract Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its associated comorbidities. Despite its efficacy, postoperative care and follow-up after MBS remains highly variable worldwide. Objective: The PARTNER study aimed to evaluate global clinical practices in the postoperative management following MBS by surveying multidisciplinary healthcare professionals . Methods: This study was an international online survey conducted between October 2024 and January 2025. A multidisciplinary team developed the questionnaire based on existing literature and international guidelines. The survey assessed five domains: follow-up care, postoperative treatment, dietary management, patient support, and measurement of surgical outcomes. Responses were analysed descriptively. Results: A total of 262 responses were received from 62 countries. Most respondents were bariatric surgeons (72.1%) working in public healthcare systems (73.3%). While 78.7% reported conducting three-month postoperative reviews, only 23.7% offered indefinite follow-up. Hybrid models of care (virtual and in-person) were common (56.9%). VTE prophylaxis and postoperative PPI use were recommended by 64.1% and 84.3% respectively. Nearly all respondents (98.1%) provided dietary advice, with protein and micronutrient supplementation widely endorsed. Only 56.1% routinely referred patients for psychological follow-up. Definitions of surgical success and failure varied widely, with inconsistent objective outcome measures. Conclusion: The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity of care worldwide.
Exercise and Atrial Fibrillation: Current Evidence, Knowledge Gaps, and Future Directions
Pham, Hoang Nhat , Abdelnabi, Mahmoud , Ibrahim, Ramzi, Sainbayar, Enkhtsogt , Truong, Hong Hieu, Habib, Eiad , Bcharah, George , Sorajja, Dan , Abdelnabi, Mahmoud , Pathangey, Girish , Chahal, Anwar A, Nhat, Hoang , Ibrahim, Ramzi, Singh, Amitoj , Arsanjani, Reza , Chahal, C. Anwar A.

Mayo Clinic

Reviews in Cardiovascular Medicine | August 6, 2025 | Volume: 26 | Issue: 7 | Pages: No page available

10.31083/rcm39200 | PMID 40776961 Get It

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, contributing to significant morbidity and mortality worldwide. The relationship between physical exercise and AF is complex, with studies showing both beneficial and potentially adverse effects. Moreover, evidence suggests a U-shaped association between exercise intensity and AF risk. Moderate exercise has been shown to reduce AF burden by improving cardiovascular risk factors, enhancing autonomic regulation, and mitigating atrial fibrosis. In contrast, excessively high-intensity endurance exercise may increase AF risk, particularly in young athletes, due to atrial stretching, dilation, fibrosis, autonomic imbalances, and heightened inflammation. The current guidelines emphasize exercise as a core lifestyle intervention for AF management, recommending moderate-intensity aerobic activity for optimal outcomes. This review examines the current evidence on the effects of exercise on AF, identifies knowledge gaps, and proposes potential future research directions.
Impact of sodium-glucose cotransporter-2 inhibitors on survival in patients with cancer therapy-related cardiac dysfunction
Farina, J M, Javadi, Niloofar , Bismee, Nadera N. , Mohammed, Amrallah A. , Narayanasamy, Hemalatha , Lester, S J, Tamarappoo, Balaji , Abbas, M, Scalia, Isabel G. , Pereyra, M, Awad, Kamal , Alsidawi, Said , Larsen, C, Ayoub, C, Arsanjani, Reza

Mayo Clinic

European Heart Journal Supplements | August 1, 2025 | Volume: 27 | Issue: Supplement_6 | Pages: No page available

10.1093/eurheartjsupp/suaf083.107 Get It

Abstract Introduction Cancer therapy-related cardiac dysfunction (CTRCD) after anthracycline-based therapy is a dreaded complication due to its significant morbidity and mortality. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) have been shown to improve cardiovascular outcomes in multiple scenarios. However, its potential benefits in patients who develop CTRCD due to anthracycline-based chemotherapy are not well established. Purpose To investigate the benefits of SGLT2i in cancer patients who develop CTRCD secondary to anthracycline-based chemotherapy. Methods All patients who underwent anthracycline therapy between 2002 and 2022 across three tertiary centers and had a diagnosis of moderate or severe CTRCD according to 2022 European Society of Cardiology (ESC) guidelines were evaluated. Baseline characteristics, echocardiograms pre and post chemotherapy, and mortality were reviewed. Kaplan Meier analysis was conducted to compare all-cause and cardiovascular mortality between patients treated with SGLT2i (both patients on chronic SGLT2i who continued their therapy following CTRCD and those who commenced the treatment after CTRCD diagnosis) and those not receiving this therapy. Results In total, 398 patients diagnosed with moderate or severe CTRCD were included; median age was 66.82 (58.07, 74.46) years and 59.29% were males. Among them, 39 (9.80%) received SGLT2i. Mortality rates at 1- and 5-years were significantly lower among patients who were on SGLT2i treatment compared to patients who were not (8.40% vs 46.30%, p= 0.0001 and 17.30% vs 65%, p= 0.0001, respectively) (Figure1). Furthermore, cardiovascular mortality rate at 5 years was significantly lower in patients receiving SGLT2i compared to patients not receiving this therapy (0% vs 11%, p= 0.046). Conclusions SGLT2i may have survival benefit in cancer patients who develop CTRCD secondary to anthracycline-based chemotherapy and might be considered as an adjunctive treatment to improve survival outcomes in this population.Figure 1.Kaplan-Meier Curves
Computed Tomography and Coronary Plaque Analysis
AlHammouri, Hashim M. , Ibrahim, Ramzi , Al-Asmar, Rahmeh, Abdelnabi, Mahmoud , Habib, Eiad , Allam, Mohamed , Pham, Hoang Nhat , Elbenawi, Hossam , Farina, Juan M. , Tamarappoo, Balaji , Jokerst, Clinton, Ayoub, Chadi , Arsanjani, Reza , Alhammouri, Hashim , Farina, Juan M , Arsanjani, Reza , Allam, Mohamed N , Nhat, Hoang , Ibrahim, Ramzi , Al-Asmar, Rahmeh , Lee, Kwan

Mayo Clinic

Tomography | July 30, 2025 | Volume: 11 | Issue: 8 | Pages: 85

10.3390/tomography11080085 | PMID 40863876 Get It

Advances in plaque imaging have transformed cardiovascular diagnostics through detailed characterization of atherosclerotic plaques beyond traditional stenosis assessment. This review outlines the clinical applications of varying modalities, including dual-layer spectral CT, photon-counting CT, dual-energy CT, and CT-derived fractional flow reserve (CT-FFR). These technologies offer improved spatial resolution, tissue differentiation, and functional assessment of coronary lesions. Additionally, artificial intelligence has emerged as a powerful tool to automate plaque detection, quantify burden, and refine risk prediction. Collectively, these innovations provide a more comprehensive approach to coronary artery disease evaluation and support personalized management strategies.
Response to Letter to the Editor Concerning the Article “Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation”
Ibrahim, Ramzi , Lim, Ghee K., Mee, Xuan Ci , Abdelnabi, Mahmoud , Habib, Eiad , Lee, Justin Z. , Lester, Steven J., Scott, Luis R. , Sorajja, Dan , Ayoub, Chadi , Pham, Hoang N, Mee, Xuan Ci , Ibrahim, Ramzi , Ibrahim, Ramzi , Lim, Ghee K., Pham, Hoang N., Farina, Juan M. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 25, 2025 | Volume: 36 | Issue: 8 | Pages: 2105-2106

10.1111/jce.70030 | PMID 40709569 Get It

Ticagrelor and sleep apnea: an international retrospective cohort study
Abdelnabi, Mahmoud , Habib, Eiad , Al-Asmar, Rahmeh, AlHammouri, Hashim M. , Ayoub, Chadi , Sweeney, John P., Sorajja, Dan , Fortuin, David, Arsanjani, Reza, Yang, Eric , Ibrahim, Ramzi , Allam, Mohamed , Pham, Hoang Nhat , Al-Asmar, Rahmeh , Yang, Eric H. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Coronary Artery Disease | July 18, 2025 | Volume: 37 | Issue: 1 | Pages: 65-67

10.1097/mca.0000000000001556 | PMID 40829057 Get It

Space Oncology: A Comprehensive Scoping Review
Niknam, Nafise , Akbarialiabad, Hossein , Kouhanjani, Mohsen Farjoud , Varghese, Lydia Johnson Kolaparambil , González, Amy Berrington de , Melin, M. Mark , Shafie’ei, Mohammad , Mousavi, Seyedeh Maryam , Hosseini, Seyed Ali , Taha, Seyed Reza , Grada, Ayman , Akbari, Zahra , Jokar-Derisi, Armita , Jurga, Marta , Das, Saswati , D’Urbano, Jessica , Hakim, Gabriella, Sadeghian, Najmeh , Tarbox, Michelle , West, Cameron , Hosseini, Seyed Hossein , Squire, Timothy , Christiansen, Rowena , Melin, Matthew M , Farjoud Kouhanjani, Mohsen , Kolaparambil Varghese, Lydia Johnson , Russomano, Thais , Murrell, D F , Leachman, Sancy A , Akbari, Zahra , Derisi, Armita Jokar , Das, Saswati , D'Urbano, Jessica , Hakim, Gabriella , Sadeghian, Najmeh , Paydar, Shahram , Tarbox, Michelle , West, Cameron , Ghorashi, Seyyed Mojtaba , Hosseini, Seyed Hossein , Squire, Timothy , Christiansen, Rowena , Berrington de Gonzalez, Amy , Leachman, Sancy A. , Kumar, Ajay , Bunick, Christopher G.

Mayo Clinic

Wilderness & Environmental Medicine | July 14, 2025 | Volume: 36 | Issue: 1_suppl | Pages: No page available

10.1177/10806032251349442 | PMID 40653854 Get It

Space exploration exposes astronauts to unique conditions such as microgravity and space radiation, potentially influencing gene expression and triggering carcinogenesis. Paradoxically, these extreme environments could uncover other pro-treatment aspects of cancer biology. Despite numerous reviews addressing these aspects in isolation, a comprehensive synthesis of the effects of space stressors on cancer development is incomplete. This scoping review aims to provide a holistic perspective on the influence of spaceflight and associated stressors—including gravitation (hyper- and microgravity), radiation, and vibration—on the potential for cancer development and altered cellular mechanisms. We adhered to the PRISMA-ScR checklist for our review. A multitiered search strategy was employed in English, starting with a preliminary keyword identification in Google Scholar and PubMed. Subsequently, the main search was conducted across five databases—Cochrane, Embase, PubMed, Scopus, and Web of Science—until 22 February 2024. All included studies were thoroughly assessed by two independent reviewers. Of the 15,553 identified articles, 158 were deemed eligible. The majority (92%) were experimental studies, predominantly cell-based (74.17%). Breast (15.19%), thyroid (13.92%), and hematopoietic (11.40%) cancers were the most frequently examined. Spaceflight stressors could affect different biological systems variably, with microgravity impacting spatial growth and metastasis, and cosmic radiation exerting both tumor-suppressive and mutagenic effects. Our findings highlight the need for large-scale, prolonged analog studies mimicking space conditions to enhance mission safety and shed light on the nuanced effects of space stressors on cancer. Additionally, further extensive studies need to be performed in the true weightlessness of spaceflight, both animal-based and on human tissue (cell cultures and potentially whole perfusion organ models), in addition to crew pre/intra/post-flight long-duration evaluations. Furthermore, this unique research avenue may reveal cancer cell sensitivities to these stressors, opening new pathways for innovative therapeutic strategies in cancer treatment.
The Angiography Pattern of Buerger’s Disease: Challenges and Recommendations
Fazeli, Bahare , Poredoš, Pavel , Stephen, Edwin , Bashar, Abul Hasan Muhammad , Kozak, Matija, Catalano, M. , Salman, Mussaad Mohammaed Al, Altarazi, Louay, Dimakakos, Evangelos , Erer, Dilek , Farkas, Katalin , Fokou, Marcus , Ionac, Mihai , Iwai, Takehisa , Karahan, Oğuz , Kashani, Daniel , Kota, Albert Abhinay , Kröger, Knut , Kubat, Emre , Premkumar, Prabhu , Marcoccia, Antonella , Pandey, Sandeep Raj , Patel, Malay , Pécsvárady, Zsolt, Polat, Adıl , Ravari, Hassan , Selvaraj, Dheepak, Sharebiani, Hiva , Stanek, Agata , Taha, Wassila , Taheri, Hossein , Yuwono, Hendro Sudjono , Zor, Mustafa Hakan , Stephen, Edwin , Bashar, Abul Hasan Muhammad , Catalano, Mariella , Dimakakos, Evangelos , Farkas, Katalin , Ionac, Mihai , Karahan, Oguz , Kashani, Daniel , Kota, Albert , Kubat, Emre , Kumar, Prabhu Prem , Marcoccia, Antonella , Polat, Adil , Ravari, Hassan , Sharebiani, Hiva , Stanek, Agata , Liew, Aaron , Antignani, Pier Luigi , Desai, Sanjay, Hüssein, Emad , Małecki, Rafał , Schernthaner, G. , Szuba, Andrzej

Mayo Clinic

Journal of Clinical Medicine | July 8, 2025 | Volume: 14 | Issue: 14 | Pages: 4841

10.3390/jcm14144841 | PMID 40725544 Get It

In 2023, the VAS international working group on Buerger’s Disease (BD) recommended two diagnostic criteria based on a prior Delphi study: “definitive” and “suspected”. The “definitive” criteria are history of smoking, typical angiography, and typical histopathological features. All three features are mandatory to confirm a “definitive” diagnosis of BD. The conundrum is—what features should be considered typical of BD angiography? According to this review, segmental occlusion of infrapopliteal arteries, corkscrew collaterals that appear to continue the occluded arterial segment (Martorell’s sign) or bypass the segmental occlusion, absence of atherosclerotic plaque or aneurysm could differentiate BD from ASO. Hence, for “typical” BD angiography, these manifestations should certainly be considered. However, data for differentiating angiography patterns of BD from the small- and medium-sized vasculitis including Behcet’s disease, scleroderma, hepatitis associated vasculitis, and anti-phospholipid syndrome are limited. Further studies for investigating the angiography pattern in BD patients in early and late presentation of BD, particularly in the patients with long-term follow up, are highly recommended.